Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model

A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibod...

Descripción completa

Detalles Bibliográficos
Autor principal: Caras, Ingrid W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381803/
https://www.ncbi.nlm.nih.gov/pubmed/32281289
http://dx.doi.org/10.1002/sctm.19-0424
_version_ 1783563121961467904
author Caras, Ingrid W.
author_facet Caras, Ingrid W.
author_sort Caras, Ingrid W.
collection PubMed
description A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibody‐mediated immunotherapy targeting CD47 and the other an antibody targeting ROR1. This article summarizes the evidence that CSCs are targeted and discusses the results of early clinical trials within the context of the CSC model.
format Online
Article
Text
id pubmed-7381803
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73818032020-07-27 Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model Caras, Ingrid W. Stem Cells Transl Med Perspectives A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibody‐mediated immunotherapy targeting CD47 and the other an antibody targeting ROR1. This article summarizes the evidence that CSCs are targeted and discusses the results of early clinical trials within the context of the CSC model. John Wiley & Sons, Inc. 2020-04-12 /pmc/articles/PMC7381803/ /pubmed/32281289 http://dx.doi.org/10.1002/sctm.19-0424 Text en © 2020 The Author. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspectives
Caras, Ingrid W.
Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_full Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_fullStr Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_full_unstemmed Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_short Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_sort two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381803/
https://www.ncbi.nlm.nih.gov/pubmed/32281289
http://dx.doi.org/10.1002/sctm.19-0424
work_keys_str_mv AT carasingridw twocancerstemcelltargetedtherapiesinclinicaltrialsasviewedfromthestandpointofthecancerstemcellmodel

Ejemplares similares